Assertio Holdings price target raised to $8 from $6 at BWS Financial

BWS Financial raised the firm’s price target on Assertio Holdings to $8 from $6 and keeps a Buy rating on the shares. The company could "significantly benefit" from this week’s new guideline set by American Society for Gastrointestinal Endoscopy related to the use of indomethacin post endoscopic retrograde cholangiopancreatography surgery, the analyst tells investors in a research note. The firm says Indocin is Assertio’s largest source of revenue and nearly all the revenue from off-line use is related to post ERCP surgery. It believes the new guidance could result in many more patients being given Indocin.